Providing patients with pharmacogenetic test results affects adherence to statin therapy: Results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial

Pharmacogenomics Journal

Volumn 14, Issue 3, 2014, Pages 272-280

  Charland, S L ^a,b   Agatep, B C ^a,c   Herrera, V ^a   Schrader, B ^a,d   Frueh, F W ^a   Ryvkin, M ^a   Shabbeer, J ^e   Devlin, J J ^f   Superko, H R ^f   Stanek, E J ^a  

^a Express Scripts   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Avalere Health LLC   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e Ariosa Diagnostics   (United States)

^f CELERA   (United States)

Author keywords

KIF6; medication adherence; pharmacogenetics; statin therapy

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENETIC RISK; HUMAN; KIF6 GENE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; MIDDLE AGED;

AGED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHARMACOGENETICS;

EID: 84901255199     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.27     Document Type: Article

References (48)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012; 125: e12-e230.
2. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation 2002; 106: 3143-3421; PMID: 12485966.
3. Grundy SM, Cleeman JI, Merz CNB, Brewer Jr. HB, Clark LT, Hunninghake DB et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. JACC 2004; 44: 720-732.
4. American Diabetes Association. Standards of Medical Care in Diabetes - 2012. Diabetes Care 2012; 35(Suppl 1): S11-S63.
5. Smith Jr SC, Benjamin EJ, Bonow RO, Braun LT, Creagerm M, Franklin BA et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-2473.
6. 2011 Top Therapeutic Classes by US Spending, IMS Health2012 http://www. imshealth.com/deployedfiles/ims/Global/Content/Corporate/PressRoom/Top-Line MarketData&Trends/2011Top-lineMarketData/Top-Therapy-Classes-by-Sales. pdfAccessed 2012.
7. 2011 Top Therapeutic Classes by U.S. Dispensed Prescriptions, IMS Health 2012 http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press Room/Top-LineMarketData&Trends/2011ToplineMarketData/Top-Therapy-Classes-by- RX.pdfAccessed on 2012.
8. Sarawate CA, Cziraky MJ, Stanek EJ, Willey VJ, Corbelli JC, Charland SL. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed? Cin Ther 2007; 29: 196-209.
9. Jackevicius CA, Mamdani M, Tu JV. Adherence with statins in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462-467.
10. Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: A systematic review. J Clin Lipidol 2010; 4: 462-471.
11. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521-530.
12. Aubert RE, Yao J, Xia F, Garavaglia SB. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Managed Care 2010; 16: 459-466.
13. Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011; 107: 1662-1666.
14. Loeppke R, Haufle V, Jinnett K, Parry T, Zhu J, Hymel P et al. Medication adherence, comorbidities, and health risk impacts on workforce absence and job performance. JOEM 2011; 53: 595-604.
15. National council on patient information and education. Enhancing prescription medicine adherence: A National Action Plan. 2007 http://www.talkaboutrx. org/documents/enhancing-prescription-medicine-adherence. pdf Accessed on November 12, 2012.
16. Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM et al. Medication adherence: a call for action. Am Heart J 2011; 162: 412-424.
17. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence. Its importance in cardiovascular disease. Circulation 2009; 119: 3028-3035.
18. Haynes RB, Ackloo E, Sahota N, Mc Donald HP, Yao X. Interventions for enhancing medication adherence (Review). The Chocrane Database of Systematic Reviews 2008 (2): CD000011; doi:10.1002/14651858.CD000011.pub3.
19. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions. Arch Int Med 2007; 167: 540-545.
20. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. JAMA 2006; 296: 2563-2571.
21. O'Donnell CJ, Nabel EG. Genomics of cardiovascular disease. N Engl J Med 2011; 365: 2098-2109.
22. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364: 1144-1153.
23. Li Y, Iakoubova OA, Shiffman D, Devlin JJ, Forrester JS, Superko HR. KIF6 polymorphism as a predictor of risk of coronary events and clinical event reduction by statins. Am J Cardiol 2010; 106: 994-998.
24. Ference BA, Yoo W, Flack JM, Clarke M. A common KIF6 polymorphism increases vulnerability to low-density lipoprotein cholesterol: two meta-analyses and a meta-regression analysis. PloS One 6: e28834.
25. Bloss CS, Madlensky L, Schork NJ, Topol EJ. Genomic information as a behavioral health intervention: can it work? Pers Med 2011; 8: 659-667.
26. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med 2008; 10: 19-32.
27. Marteau TM, French DP, Griffin SJ, Prevost AT, Sutton S, Watkinson C et al. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviors. Cochrane Database of Systematic Reviews 2010 (10): CD007275; doi:10.1002/14651858.CD007275.pub2.
28. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after genetic risk assessment for Alzheimer Disease: The REVEAL Study. Alzheimer Dis Assoc Discord 2008; 22: 94-97.
29. Ware JE, Kosiniski M, Keller SD. A 12-item Short Form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-233.
30. Morisky DE, Green LW, Levine DM. Concurrent predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
31. Germer S, Holland MJ, Higuchi R. High-throughput SNP allele frequency determination in pooled DNA samples by kinetic PCR. Genome Res 2000; 10: 258-266.
32. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. As empirical bases for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008; 46: 1125-1133.
33. Kareter AJ, Parker MM, Moffet HH, Ahmed AM, Schmittdel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Services Res 2009; 44: 1640-1661.
34. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. CMRO 2009; 25: 2303-2310.
35. McBride CM, Bepler G, Lipkus IM, Lyna P, Samsa G, Albright J et al. Incorporating genetic suseptability feedback into a smoking cessation program for African- American smokers with low income. Cancer Epi Biomark Prev 2002; 11: 521-528.
36. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. NEJM 2011; 364: 524-534.
37. Foster MW, Mulvihill JJ, Sharp RR. Evaluating the utility of personal genomic information. Genet Med 2009; 11: 570-574.
38. Benner JS, Tiece JC, Ballantyne CM, Prasad C, Bullano MF, Willey VJ et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004; 22(Suppl 3): 13-23.
39. Smith DH, Kramer JM, Perrin N, Platt R, Roblin DW, Land K et al. A randomized trial of direct-to-patient communication to enhance adherence to b-blocker therapy following myocardial infarction. Arch Int Med 2008; 168: 477-483.
40. Shiffman D, O'Meara ES, Bare LA, Rowland CM, Louie JZ, Arellano AR et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2008; 28: 173-179.
41. Iakoubova OA, Tong CH, Rowland CM, Kirchgessner TG, Young BA, Arellano AR et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol 2008; 51: 435-443.
42. Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2008; 51: 449-455.
43. Shiffman D, Sabatine MS, Louie JZ, Kirchgessner TG, Iakoubova OA, Campos H et al. Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. Am J Cardiol 2010; 105: 1300-1305.
44. Assimes TL, Hólm H, Kathiresan S, Reilly MP, Thorleifsson G, Voight BF et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. JACC 2010; 56: 1552-1563.
45. Hopewell JC, Parish S, Clarke R, Armitage J, Bowman L, Hager J et al. MRC/BHF Heart Protection Study Collaborative Group. No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J Am Coll Cardiol 2011; 57: 2000-2007.
46. Ridker PM, MacFadyen JG, Glynn RJ, Chasman DI, Ridker PM, MacFadyen JG et al. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention. Circ Cardiovasc Genet 2011; 4: 312-317.
47. Arsenault BJ, Boekholdt SM, Hovingh GK, Hyde CL, Demicco DA, Chatterjee A et al. on behalf of the TNT and IDEAL Investigators. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipidlowering prospective studies. Circ Cardiovasc Genet 2012; 5: 51-57.
48. Raebel MA, Carrolll NM, Schroeder EB, Bayliss EA. Importance of including early nonadherence in estimates of medication adherence. Ann Pharmacother 2011; 45: 1053-1060.